Publications by authors named "William Pelletiers"
Article Synopsis
- The objective of the study was to create a reference standard and audit framework for pharmaceutical companies to enhance diversity in clinical trials, following guidelines from the US FDA and other stakeholders.
- The research involved analyzing policies from 50 pharmaceutical companies, selected based on their market capitalization, using data from their websites and annual reports as well as guidance from various health organizations.
- Key findings established 14 themes to improve diversity in clinical trials, including setting enrollment targets that reflect the affected populations, broadening eligibility criteria, and ensuring diverse workforce representation in trial management.
Background: Equitable representation of members from historically marginalized groups is important in clinical trials, which inform standards of care. The goal of this study was to characterize the demographics and proportional subgroup reporting and representation of participants enrolled in randomized controlled trials (RCTs) of antibacterials used to treat Staphylococcus aureus infections.
Methods: We examined randomized controlled registrational and strategy trials published from 2000 to 2021 to determine the sex, race, and ethnicity of participants.